Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia

Sujata M Bhavnani; Alan Forrest; Jeffrey P Hammel; George L Drusano; Christopher M Rubino; Paul G Ambrose

doi:10.1016/j.diagmicrobio.2008.04.008

Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia

Diagn Microbiol Infect Dis. 2008 Sep;62(1):99-101. doi: 10.1016/j.diagmicrobio.2008.04.008. Epub 2008 Jun 25.

Authors

Sujata M Bhavnani¹, Alan Forrest, Jeffrey P Hammel, George L Drusano, Christopher M Rubino, Paul G Ambrose

Affiliation

¹ Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206-1072, USA. [email protected]

PMID: 18583085
DOI: 10.1016/j.diagmicrobio.2008.04.008

Abstract

Exposure-response analyses were performed using data from 89 patients (10 clinical trials) with Streptococcus pneumoniae community-acquired pneumonia who received quinolones. Relationships between the free-drug AUC/MIC ratio and clinical and microbiologic response were identified. Such data may be useful to establish prior expectations for the no-treatment effect when conducting noninferiority clinical trials.

MeSH terms

Anti-Bacterial Agents* / pharmacokinetics
Anti-Bacterial Agents* / therapeutic use
Area Under Curve
Community-Acquired Infections / drug therapy*
Community-Acquired Infections / epidemiology
Community-Acquired Infections / microbiology
Humans
Microbial Sensitivity Tests
Pneumonia, Pneumococcal / drug therapy*
Pneumonia, Pneumococcal / epidemiology
Pneumonia, Pneumococcal / microbiology
Quinolones* / pharmacokinetics
Quinolones* / therapeutic use
Streptococcus pneumoniae / drug effects*
Treatment Outcome

Substances

Anti-Bacterial Agents
Quinolones